Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
April 30, 2021 12:15 PM 3 min read

4 Stocks At 52-Week Lows That Could Bounce

by Chris Katje Benzinga Staff Writer
Follow

ArticleFeaturedTickersList12345!!!

An important indicator for investors to consider could be a stock’s 52-week trading range, the range showing the lowest and highest price a particular stock traded over the trailing year.

Finding stocks trading near 52-week lows can be a strategy to find fallen companies that could still have fundamentals, a story in place and could be rebound candidates.

Here is a look at four stocks at 52-week lows that could bounce.

Splunk: Shares of Splunk Inc (NASDAQ:SPLK) are down only 2% over the last 52 weeks. Despite the small decline, shares are down significantly from their peak level of $225.89 hit in August.

The company reported fourth-quarter revenue of $745 million, which was a 6% year-over-year decline. Full-year revenue of $2.23 billion was down 5% year-over-year.

The company has grown its data-to-everything platform and saw cloud revenue up 72% to $171 million in the fourth quarter. The company is estimating revenue of $480 million to $500 million, which would be up from the $434.1 million reported in last year’s comparable period.

Related Link: ROCE Insights For Splunk 

iRhythm: Digital healthcare company iRhythm Technologies Inc (NASDAQ:IRTC) offers ZIO, which can diagnose irregular heart rhythms quickly and potentially prevent more serious medical events like a stroke from happening.

The company reported revenue of $78.8 million, up 33% year-over-year in the fourth quarter. Full-year revenue for iRhythm was $265.2 million, up 24% year-over-year.

The company has less than 20% penetration in its core market and is seeking to expand to additional regions.

Shares of iRhythm have traded between $76.14 and $286.19 over the last 52 weeks.

Meten EdtechX Education Group: A former SPAC, Meten EdutchX Education Group Ltd (NASDAQ:METX), has fallen from a high of $13.03 to $1.89.

The company offers English language training in China — the company’s segments are adults, juniors and online — and was hurt by the COVID-19 pandemic.

In the last fiscal year, revenue fell 38% year-over-year for the company with declines of 58% for adults and 22% for juniors.

The company announced this week that student enrollment in the junior segment was up 483% in the first quarter and showing signs of a return to pre-pandemic growth. Meten is seeking additional growth with the offering of three additional languages and exam prep offerings.

Blockchain education was also announced as a new service in April.

Quidel: Diagnostic testing company Quidel Corporation (NASDAQ:QDEL) had quite the year with shares hitting a high of $306.72. But this week shares hit a new 52-week low of $105.93.

Strong demand for the company’s SARS tests for COVID-19 testing has been a huge driver of sales.

The company reported $908.2 million in fourth-quarter revenue, up 432% year-over-year. COVID-19 related revenue represented $678.7 million of the total.

In the last fiscal year, the company had $1.66 billion in revenue, up 211% year-over-year. COVID-19-related revenue for the full year was $1.16 billion.

The company has launched additional products and is still seeing strong demand for COVID-19 tests. The selloff in shares implies the company’s growth will fade with the pandemic lessening or shares being too inflated due to the COVID-19 trade.

Meeting somewhere in the middle, Quidel could be ripe for a bounce. The company will report its quarterly financials on May 6.

(Photo by Mariah Solomon on Unsplash)

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Long IdeasPenny StocksTop StoriesTrading Ideas52-week LowChinaSPACSPACs
IRTC Logo
IRTCiRhythm Holdings Inc
$152.22-%
Overview
QDEL Logo
QDELQuidelOrtho Corp
$29.21-%
IRTC Logo
IRTCiRhythm Holdings Inc
$152.22-%
Overview
QDEL Logo
QDELQuidelOrtho Corp
$29.21-%
Comments
Loading...